Cantor Fitzgerald upgraded shares of Bradmer Pharmaceuticals (TSE:GLX – Free Report) to a strong-buy rating in a research report report published on Tuesday,Zacks.com reports.
Bradmer Pharmaceuticals Stock Performance
Read More
- Five stocks we like better than Bradmer Pharmaceuticals
- 3 Fintech Stocks With Good 2021 Prospects
- Nebius Slides Post-Earnings: A Long-Term Buy Opportunity?
- 3 Warren Buffett Stocks to Buy Now
- NVIDIA Stock: A Market Barometer in Tech’s Turbulent Times
- What Are Some of the Best Large-Cap Stocks to Buy?
- Palantir Stock Nears Bear Market Territory – Why and What’s Next?
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
